January 7, 2019 / 6:07 AM / 3 months ago

BRIEF-Vifor Pharma Receives Positive Phase-I Trial Results For Oral Ferroportin Inhibitor

Jan 7 (Reuters) - VIFOR PHARMA AG:

* VIFOR PHARMA RECEIVES POSITIVE PHASE-I TRIAL RESULTS FOR ORAL FERROPORTIN INHIBITOR

* DATA IN HEALTHY VOLUNTEERS SHOWS FAVORABLE SAFETY/TOLERABILITY PROFILE

* PHASE-II STUDY IN BETA-THALASSEMIA PATIENTS TO BEGIN IN SECOND HALF OF 2019

* EARLY RESULTS TRANSLATE WELL FROM PRECLINICAL MODELS TO HUMANS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below